Document Detail

Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group.
MedLine Citation:
PMID:  2407265     Owner:  NLM     Status:  MEDLINE    
We report on the distress associated with physical symptoms in 761 male hypertensive patients enrolled in a clinical trial of the effects of captopril, methyldopa or propranolol on quality of life. Educational level at entry into the trial showed a negative association with a series of physical symptom distress items among patients not previously treated with antihypertensive medications but no association with symptoms among the previously treated. Over the 24 weeks of therapy captopril as monotherapy was associated with no change from baseline in distress in all symptoms examined. In contrast, distress increased in the methyldopa treated patients for dry mouth and blurred vision. Propranolol treated patients had increased "trouble getting breath," bradycardia, shortness of breath or wheezing, and blurred vision. Between group comparisons revealed significant differences favorably comparing captopril to both methyldopa and propranolol in regard to fatigue, and blurred vision, as well as to methyldopa alone for dry mouth and "feeling worn out." There were significant differences as well between captopril and propranolol with patients on propranolol worsening in bradycardia. Other comparisons of patients on propranolol and methyldopa monotherapy showed propranolol patients worsening in bradycardia and loss of taste, but methyldopa patients reported more dry mouth and feeling worn out than those on propranolol. The addition of hydrochlorothiazide to therapy worsened total physical symptom distress scores for methyldopa and propranolol patients. This study confirms the value of methods which assess the degree of distress associated with symptoms commonly reported by hypertensive patients receiving antihypertensive medications. This approach can be useful in establishing a treatment regimen least likely to cause distress and can be of value in preserving quality of life, preventing noncompliance, and withdrawal from treatment.
J A Schoenberger; S H Croog; A Sudilovsky; S Levine; R M Baume
Related Documents :
14643565 - Mini international neuropsychiatric schedule: clinical utility and patient acceptance.
19522315 - Orofacial and general disorders in oral medicine patients. oral and medical history.
12054145 - The concerns of patients under palliative care and a heart failure clinic are not being...
19260095 - Coping strategies and iq in psychogenic movement disorders and paralysis.
9835435 - The outcome of patients with upper airway obstruction transported to a regional paediat...
23363895 - Relation of inflammatory and oxidative markers to the occurrence and recurrence of pers...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of hypertension     Volume:  3     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  1990 Feb 
Date Detail:
Created Date:  1990-04-10     Completed Date:  1990-04-10     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  123-32     Citation Subset:  IM    
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antihypertensive Agents / adverse effects*
Captopril / administration & dosage,  adverse effects
Clinical Trials as Topic
Double-Blind Method
Drug Therapy, Combination
Educational Status
Hydrochlorothiazide / administration & dosage,  adverse effects
Hypertension / drug therapy*,  physiopathology,  rehabilitation
Methyldopa / administration & dosage,  adverse effects
Middle Aged
Multicenter Studies as Topic
Propranolol / administration & dosage,  adverse effects
Quality of Life*
Random Allocation
United States
Reg. No./Substance:
0/Antihypertensive Agents; 525-66-6/Propranolol; 555-30-6/Methyldopa; 58-93-5/Hydrochlorothiazide; 62571-86-2/Captopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Poxvirus-based vectors as vaccine candidates.
Next Document:  Some problems with antihypertensive drug studies in the context of the new guidelines.